Viatris (XTER:VIA) ROCE % : 2.48% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viatris ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Viatris's annualized ROCE % for the quarter that ended in Sep. 2024 was 2.48%.

Viatris ROCE % Historical Data

The historical data trend for Viatris's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris ROCE % Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

2.53

-0.56

-0.06

7.97

1.84

Viatris Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															5.21	-6.91	3.46	-2.56	2.48

Viatris ROCE % Calculation

Viatris's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	711.592	/	( ( (47220.957 - 6368.413)	+	(43727.603 - 7131.876) )	/ 2 )
	=	711.592	/	( (40852.544	+	36595.727)	/ 2 )
	=	711.592	/	38724.1355
	=	1.84 %

Viatris's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	850.904	/	( ( (42111.57 - 7161.847)	+	(40323.444 - 6768.672) )	/ 2 )
	=	850.904	/	( ( 34949.723	+	33554.772 )	/ 2 )
	=	850.904	/	34252.2475
	=	2.48 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Viatris (XTER:VIA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Viatris ROCE % Related Terms

Thank you for viewing the detailed overview of Viatris's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (XTER:VIA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany VIA:Germany VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.